MetaCap

CapsoVision Inc. (CV)

NASDAQ: CVHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD

6.11-0.20 (-3.17%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$327.56M
EPS (TTM)
-$0.42
52-week range
4.50 – 15.37
Day range
6.01 – 6.37
Volume / Avg
178.65K / 173.59K
Beta
—

52-week range

$4.50$15.37

CV stock today

CapsoVision (CV) closed at $6.11 on Nov 20, down 3.17% (-$0.20), versus the S&P 500's 3.70% decline. Shares are 60.2% below their 52-week high of $15.37, set on Dec 11, 2025 and 35.8% above the 52-week low of $4.50, near the bottom of the past year's range. CV is down 42.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 16.8%.

CapsoVision has posted a net loss over the last twelve months (EPS of -$0.42), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CapsoVision

Company profile

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services.

Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
CEO
Mr. Kang-Huai Wang
Headquarters
Saratoga, CA
Employees
99
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, CapsoVision generated $13.6 million in revenue, up 15.3% from fiscal 2024. CapsoVision reported a net loss of $25.3 million, compared with a loss of $19.9 million a year earlier. Gross margin was 52.9% (down from 54.2%) and operating margin -188.3%.

CapsoVision annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$13.55M$11.76M
Growth+15.29%—
Net income$-25.32M$-19.90M
EPS (diluted)$-1.03$-9.85

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$9.50+55.48%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.15 vs $-0.15

CV news

All CV news

CapsoVision peers

Health Care sector
CV peer companies
CompanyPrice% ChgMarket capCompare
ELMDElectromed Inc.22.98-1.20%$187.84Mvs CV
FOCLEDAP TMS S.A. ADR2.61-7.45%$123.25Mvs CV
VANIVivani Medical Inc.1.14+4.59%$102.83Mvs CV
STXSStereotaxis Inc.0.9422-6.71%$95.03Mvs CV
HSDTSolana Company Class A1.49-10.24%$93.70Mvs CV
NRXSNeuraxis Inc.4.22-6.22%$59.90Mvs CV
HYPRHyperfine Inc. Class A0.5465+4.27%$57.96Mvs CV
OMOutset Medical Inc.2.81-3.44%$53.03Mvs CV

Indexes, lists and sector

CapsoVision stock FAQ

What is CapsoVision's stock price today?

CV last traded at $6.11 as of Nov 20, 4:00 PM EST, down 3.17% on the day. Prices are delayed at least 15 minutes.

Who is CapsoVision's CEO?

Mr. Kang-Huai Wang is the chief executive officer of CapsoVision Inc., which has about 99 employees.

What is the CV 52-week high?

The 52-week high for CV is $15.37 and the 52-week low is $4.50. The stock is currently 60.2% below its high.

Compare CV